open access

Vol 66, No 5 (2015)
Review paper
Submitted: 2015-07-06
Accepted: 2015-07-21
Published online: 2015-10-12
Get Citation

Thyroid hormones in the central nervous system (CNS) and their effect on neoplasm formation, particularly on the development and course of glioblastoma multiforme — research hypothesis

Paweł Nauman
DOI: 10.5603/EP.2015.0055
·
Pubmed: 26457500
·
Endokrynol Pol 2015;66(5):444-459.

open access

Vol 66, No 5 (2015)
Review Article
Submitted: 2015-07-06
Accepted: 2015-07-21
Published online: 2015-10-12

Abstract

The present study is aimed to present the potential role of thyroid hormones (TH) in the pathogenesis of glioblastoma multiforme (GBM). In first part of this presentation the effect of general homeostasis of TH on GBM formation and course was shown. Then the evidence concerning present state of the knowledge about active transport of TH to the brain, the role of iodothyronine deiodinase type 2 and 3 in the setting concentration of T3 in the brain and GBM cells, and finally knowledge about the role of genomic (TH nuclear receptors THRA and THRB) and non-genomic modes (membrane integrin receptor αvβ3) of action of TH and its importance for GBM was outlined. The last part of this presentation was devoted to generally approved signalling pathways leading to the formation and the clinical course of GBM, showing at the same time evidence that each of the pathways is affected by particular TH actions. In conclusion it is suggested that TH is one of the pathogenetic factors for GBM and as such can have practical implications for the formation and course and treatment of this tumour. (Endokrynol Pol 2015; 66 (5): 444–459)

Abstract

The present study is aimed to present the potential role of thyroid hormones (TH) in the pathogenesis of glioblastoma multiforme (GBM). In first part of this presentation the effect of general homeostasis of TH on GBM formation and course was shown. Then the evidence concerning present state of the knowledge about active transport of TH to the brain, the role of iodothyronine deiodinase type 2 and 3 in the setting concentration of T3 in the brain and GBM cells, and finally knowledge about the role of genomic (TH nuclear receptors THRA and THRB) and non-genomic modes (membrane integrin receptor αvβ3) of action of TH and its importance for GBM was outlined. The last part of this presentation was devoted to generally approved signalling pathways leading to the formation and the clinical course of GBM, showing at the same time evidence that each of the pathways is affected by particular TH actions. In conclusion it is suggested that TH is one of the pathogenetic factors for GBM and as such can have practical implications for the formation and course and treatment of this tumour. (Endokrynol Pol 2015; 66 (5): 444–459)

Get Citation

Keywords

thyroid hormones (TH); glioblastoma multiforme (GBM)

About this article
Title

Thyroid hormones in the central nervous system (CNS) and their effect on neoplasm formation, particularly on the development and course of glioblastoma multiforme — research hypothesis

Journal

Endokrynologia Polska

Issue

Vol 66, No 5 (2015)

Article type

Review paper

Pages

444-459

Published online

2015-10-12

Page views

1801

Article views/downloads

2797

DOI

10.5603/EP.2015.0055

Pubmed

26457500

Bibliographic record

Endokrynol Pol 2015;66(5):444-459.

Keywords

thyroid hormones (TH)
glioblastoma multiforme (GBM)

Authors

Paweł Nauman

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl